| 21-May-13 01:37PM | Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript) at Seeking Alpha |
| 07:00AM | 2013 FDA Drug Approval Calendar at TheStreet |
| 17-May-13 01:04PM | SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials |
| 16-May-13 01:23PM | Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care Innovation Wall Street Transcript |
| 15-May-13 08:31AM | 2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play at Seeking Alpha |
| 14-May-13 08:16AM | 3 Biotech Stocks With Potential at Seeking Alpha |
| 10-May-13 08:30AM | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Marketwired |
| 08:30AM | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Marketwire |
| 07:00AM | Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin at TheStreet |
| 09-May-13 02:23PM | Sarepta Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha +5.32% |
| 12:46PM | Facebooks Potential Waze Purchase, Sarepta Doesnt Fall As Hard as Expected and 3 Other Hot Stocks at Wall St. Cheat Sheet |
| 12:21PM | Sarepta climbs after saying documents to be submitted this month at theflyonthewall.com |
| 11:05AM | Sarepta's Meaningless Q1 Results at Motley Fool |
| 09:46AM | Sarepta Therapeutics Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet |
| 08:00AM | Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN |
| 07:49AM | Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN |
| 07:07AM | Q1 2013 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN |
| 07:00AM | Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments Marketwired |
| 07:00AM | Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments Marketwire |
| 12:07AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online |
| 08-May-13 06:18PM | Why Questcor Is Undervalued at Motley Fool |
| 07-May-13 08:30AM | Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus Marketwired |
| 08:30AM | Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus Marketwire |
| 06-May-13 09:21AM | Leaders of TheStreet's Drug Approval Contest at TheStreet |
| 04-May-13 08:00AM | April's Unhealthiest Stocks at Motley Fool |
| 07:00AM | The Best- And Worst-Performing Biotech Stocks, April 26 to May 3 at Forbes |
| 02-May-13 12:19AM | 3 Biggest Biotech Crashes in April at Motley Fool |
| 01-May-13 05:00PM | Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner at TheStreet +7.27% |
| 29-Apr-13 11:07AM | Sarepta (SRPT) Targets Unmet Medical Need in the Treatment of Duchenne Muscular Dystrophy; Developing First Drug with the Promise of Stopping Fatal Progressive Disease Wall Street Transcript |
| 05:51AM | NewLink Genetics: Looking To Join The Industry's Largest Movers at Seeking Alpha |
| 26-Apr-13 04:05PM | Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013 Marketwired |
| 04:05PM | Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013 Marketwire |
| 08:15AM | Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! at TheStreet |
| 25-Apr-13 09:25AM | Sarepta: Staying Long and Strong at TheStreet |
| 09:00AM | When Twitter Rogues Move Markets: A Timeline at BusinessWeek |
| 05:01AM | Sarepta Therapeutics: Irrational Exuberance at Seeking Alpha |
| 24-Apr-13 08:30AM | Quickly Approaching Biopharma Catalyst Events at Seeking Alpha |
| 23-Apr-13 02:58PM | A Biotech Firm's Ultimate Decision: To Finance, To Find A Partner Or To Go Bankrupt at Seeking Alpha |
| 01:54PM | Are These Billion-Dollar Biotechs Overvalued? at Motley Fool |
| 10:38AM | Analyzing Market Efficiency: Why Future Catalysts Imply Sanuwave Still Has Room To Double at Seeking Alpha |
| 22-Apr-13 10:31AM | 5 Hot Stocks: Facebooks Home Fails To Dazzle, Check Points Lukewarm Earnings, and Six Flags Sets A Record at Wall St. Cheat Sheet |
| 10:24AM | Want to Invest in Biotech? Think Like a Venture Capitalist at Motley Fool |
| 01:02AM | Coverage initiated on Sarepta Therapeutics by Needham Briefing.com |
| 21-Apr-13 05:15AM | 5 of Last Week's Biggest Losers at Motley Fool |
| 20-Apr-13 06:24PM | Here's What This 2,115% Gainer Has Been Buying at Motley Fool |
| 12:30PM | This Week in Biotech: Part 1 at Motley Fool |
| 08:00AM | The Best- And Worst-Performing Biotech Stocks, April 12 to April 19 at Forbes |
| 06:45AM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 19-Apr-13 05:01PM | Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard at TheStreet |
| 10:28AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 18-Apr-13 05:41PM | Personalized Cystic Fibrosis Drugs Get A Booster Shot at Forbes |
| 04:08PM | 3 Analyst Calls Worth Noting on Tuesday at Motley Fool |
| 04:05PM | Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference Marketwired |
| 04:05PM | Sarepta Therapeutics to Present Company Overview at the Needham Annual Healthcare Conference Marketwire |
| 03:10PM | FDA Says, "Call Me Maybe" at Motley Fool |
| 09:28AM | Thursday's BioPharma Trade Movers at Seeking Alpha |
| 17-Apr-13 03:02PM | Sarepta: What's Going On? at Seeking Alpha |
| 02:53PM | Telecoms Disconnected as These 2 Stocks Tumbled at Motley Fool |
| 01:29PM | Nasdaq stocks posting largest percentage decreases AP |
| 11:27AM | Why Sarepta Is A Good Buy With Or Without Accelerated Approval at Seeking Alpha |
| 07:19AM | Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy at Seeking Alpha |
| 16-Apr-13 07:28PM | Nasdaq stocks posting largest percentage decreases AP -13.38% |
| 06:03PM | Facebook In Talks With Apple and Microsoft and 4 Other Hot Stocks at Wall St. Cheat Sheet |
| 05:45PM | [video] Options Action: SRPT Down 13% Today at CNBC |
| 05:00PM | [video] Stock Pops & Drops at CNBC |
| 04:11PM | Stocks Rebound Mirrors Markets After Madrid, London Bombings at TheStreet |
| 03:11PM | Stocks, Gold Bounce Back as Coke, J&J Beat Forecasts at TheStreet |
| 02:06PM | Sarepta Therapeutic Gets Booed and 4 More Analysts Downgrades To Know at Wall St. Cheat Sheet |
| 01:21PM | Nasdaq stocks posting largest percentage decreases AP |
| 12:41PM | Why Sarepta Therapeutics Shares Tumbled at Motley Fool |
| 12:26PM | A Key Exchange On Sarepta Therapeutics' Promising Muscular Dystrophy Drug at Forbes |
| 11:00AM | Stocks, Gold Bounce Back After Boston Attacks at TheStreet |
| 11:00AM | 2 Views on Sarepta's FDA News at Motley Fool |
| 10:20AM | Sarepta tumbles after FDA requests more data on drug at theflyonthewall.com |
| 10:04AM | Sarepta Is a Gamble Worth Taking at Motley Fool |
| 09:54AM | Sarepta Stock Gaps Down On Today's Open (SRPT) at TheStreet |
| 09:32AM | Sarepta shares fall on FDA guidance on drug, but analysts divided at Reuters |
| 08:56AM | Stock Downgrades: Strayer Education Sent to Back of Class at Minyanville |
| 08:39AM | Investor Watch List: Week of April 15 2013 at Seeking Alpha |
| 08:32AM | Coca-Cola pops on strong results optionMONSTER |
| 08:32AM | Coca Cola pops on strong results optionMONSTER |
| 08:20AM | Ahead of the Bell: Sarepta shares slide AP |
| 07:25AM | A Proactive FDA Is Already Reviewing Sarepta's Muscular Dystrophy Drug (Updated) at TheStreet |
| 05:59AM | Sarepta downgraded to Market Perform from Outperform at Leerink theflyonthewall.com |
| 15-Apr-13 06:55PM | On The Fly: After Hours Movers at theflyonthewall.com |
| 05:29PM | A Proactive FDA Is Already Reviewing Sarepta's Muscular Dystrophy Drug at TheStreet |
| 05:15PM | After-Hours Buzz: RHT, HCA, NTGR & More at CNBC |
| 05:02PM | BRIEF-Sarepta Therapeutics shares down 9.5 pct after the bell at Reuters |
| 05:00PM | Sarepta Therapeutics Inc to Discuss Update on FDA's Consideration of Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes - Call scheduled for 5:00 pm ET today CCBN |
| 05:00PM | Harmonic Earnings Call scheduled for 5:00 pm ET today CCBN |
| 04:58PM | Sarepta Drops 10% After FDA Asks for More Info at Barrons.com |
| 04:46PM | FDA asks for additional info on Sarepta's muscular dystrophy drug at Reuters |
| 04:32PM | Sarepta says all eteplirsen manufacturing and development continues as planned theflyonthewall.com |
| 04:11PM | InPlay: Sarepta Therapeutics announces FDA will consider accelerated approval for eteplirsen after further review of data on dystrophin and clinical outcomes Briefing.com |
| 04:10PM | Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes Marketwired |
| 04:10PM | Sarepta Therapeutics Announces FDA Will Consider Accelerated Approval for Eteplirsen After Further Review of Data on Dystrophin and Clinical Outcomes Marketwire |
| 12-Apr-13 04:24PM | Is RNA Drug Development Coming of Age? at Motley Fool |
| 04:22PM | 3 Speculative Biotech Stocks to Buy Now at Motley Fool |
| 10:13AM | Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug at TheStreet |
| 11-Apr-13 04:42PM | Two Biotech Movers with Upside Potential at Motley Fool |
